Essential Hypertension
Conditions
Brief summary
This is an 8-week, randomized, double-blind Phase 3, multicentre study to determine the optimal dose of AZM and AML in combination therapy and to compare efficacy and tolerability of the combined therapy to each of the monotherapy in essential hypertensive subjects who are not adequately controlled on AZM and AML monotherapy.
Interventions
DRUGAZM X mg + AML Y mg
tablet, single dose, QD, oral administration
DRUGAZM X mg + AML Y' mg
tablet, single dose, QD, oral administration
DRUGAZM X' mg + AML Y mg
tablet, single dose, QD, oral administration
DRUGAZM X' mg + AML Y' mg
tablet, single dose, QD, oral administration
DRUGAZM X mg
tablet, single dose, QD, oral administration
DRUGAZM X' mg
tablet, single dose, QD, oral administration
DRUGAML Y mg
tablet, single dose, QD, oral administration
DRUGAML Y' mg
tablet, single dose, QD, oral administration
Sponsors
Celltrion
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Single-blind Run-in period, Double-blind Treatment period
Eligibility
Sex/Gender
ALL
Age
19 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Subjects voluntarily agree to participate in the trial and signed the written ICF, after listening to the purpose, method, and effect of clinical trial * Male or female adult subjects (Legal minimum age of adult requirement is country specific, and requirement of current country specific regulations will be applied) below the age of 75 years, inclusive * Subjects with mild-to-moderate essential hypertension * Subjects who are capable of understanding and complying with protocol requirements
Exclusion criteria
* Subjects who have msitSBP \>180 mmHg or msitDBP \>110 mmHg; Subjects who have difference in the blood pressure between 3 measurements (confirmed by a second set of three measurements; 3 sitting systolic BP (sitSBP) measurements differing by more than 20 mmHg or 3 sitting diastolic BP (sitDBP) measurements differing by more than 10 mmHg) * Secondary hypertension, Symptomatic orthostatic hypotension * Clinically significant Electrocardiogram (ECG) abnormalities, Severe heart disease, Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically significant arrhythmia, Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve * Severe cerebrovascular disease, Known moderate or malignant retinopathy within the past 6 months; History of unexplained syncope within the prior 2 years, or a known syncopal disorder * Significant thyroid disease, Type 1 or 2 diabetes mellitus with poor glucose control, Wasting disease, Autoimmune diseases, Connective tissue disease * Subjects who have clinically significant laboratory abnormalities : creatinine clearance \< 30 mL/min, serum creatinine \> 2 mg/dL or \> 200 μmol/L, serum potassium \<3.5 mmol/L or \> 5.5mmol/L, alanine aminotransferase or aspartate aminotransferase \> 3 × upper limit normal (ULN) * Any surgical or medical condition of the gastrointestinal tract that might significantly alter the absorption, distribution, metabolism, or excretion of the drug * Positive for HIV, HCV Ab, and/or HBsAg * History of drug or alcohol abuse within the past 1 year * Subjects who are pregnant or lactating women, women suspected of being pregnant, women who wish to be pregnant during the study, or women of child-bearing potential who are not using medically acceptable methods of contraception * Any chronic inflammatory condition needing chronic anti-inflammatory therapy, A known hypersensitivity to any main excipients and components of the investigational drugs or other drugs in the same class, Subjects who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin-converting enzyme inhibitors or angiotensin II subtype 1 receptor blocker * Subjects who have received any investigational product within 28 days prior to screening or is currently participating in another investigational study * Subjects who are required to take excluded medications at any point during the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| msitSBP | after 8 weeks of treatment | msitSBP change from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| msitDBP | after 8 weeks of treatment | msitDBP change from baseline |
| msitSBP | after 4 weeks of treatment | msitSBP change from baseline |
| Proportion of subjects achieving msitSBP < 140 mmHg and/or ΔmsitSBP ≥ 20 mmHg | after 4, 8 weeks of treatment | — |
| Proportion of subjects achieving msitDBP < 90 mmHg and/or ΔmsitDBP ≥ 10 mmHg | after 4, 8 weeks of treatment | — |
Countries
South Korea
Outcome results
None listed